安徽康瓴药业

Anhui Kangling Pharmaceutical is a clinical-stage biotechnology company headquartered in Hefei, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing significant unmet medical needs in oncology, immunology, and metabolic disorders through its proprietary drug discovery engine. Its lead candidate, KL-001, is a selective small molecule inhibitor currently undergoing Phase 1 clinical evaluation for the treatment of advanced solid tumors. Kangling is led by a team of experienced industry veterans with extensive backgrounds in global pharmaceutical R&D. The company aims to leverage its scientific expertise to deliver high-quality, differentiated medicines for patients worldwide.